US Pharma Faces First Drug Pricing Fight Of 2021
Executive Summary
A $16bn provision to increase rebates in the US Medicaid program is a surprise inclusion in the COVID relief package moving through Congress. It looks like an uphill fight for industry to stop it from happening.
You may also be interested in...
Don’t Let The Quiet Fool You: The US Drug Pricing Debate Is At A Critical Point
There won’t be a lot of legislative action in Congress in the weeks following passage of the $1.9tn American Rescue Plan. But the coming months are a critical time for the drug industry to try to set the terms for how it is treated in the next major bill later this year, and the stakes could not be higher.
Medicaid Rebate Reform: A Sign Of Minimal Drug Pricing Threats Or A Warning Of More To Come?
House Democrats push to remove the current limit on Medicaid rebates in upcoming COVID-19 relief package would likely leave many drug companies unscathed, but some expect bigger ticket drug pricing items will soon be on the agenda.
Medicaid Rebate Ceiling Raised To 125% In Senate Legislation
Senate Finance Committee's drug pricing bill would also exclude authorized generics from calculation of average manufacturer prices and rebates and authorize installment-type payments for curative gene therapies.